{"organizations": [], "uuid": "4e58625acf4dfad45576230467b771459588c676", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-five-prime-therapeutics-posts-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Five Prime Therapeutics posts 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T01:03:00.000+02:00", "replies_count": 0, "uuid": "4e58625acf4dfad45576230467b771459588c676"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-five-prime-therapeutics-posts-4q-loss.html", "ord_in_thread": 0, "title": "Five Prime Therapeutics posts 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "south san francisco", "sentiment": "none"}], "organizations": [{"name": "prime therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $29.2 million in its fourth quarter.\nThe South San Francisco, California-based company said it had a loss of $1.04 per share.\nThe results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.29 per share.\nThe biotech company that develops treatments targeting cancer and autoimmune diseases posted revenue of $13.2 million in the period.\nFor the year, the company reported that its loss widened to $150.2 million, or $5.38 per share. Revenue was reported as $39.5 million.\nFive Prime Therapeutics shares have declined 15 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $18.64, a decrease of 62 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on FPRX at https://www.zacks.com/ap/FPRX", "external_links": [], "published": "2018-02-28T01:03:00.000+02:00", "crawled": "2018-02-28T01:27:32.004+02:00", "highlightTitle": ""}